Home / Themes / Therapeutics '25: Pain Management

Therapeutics '25: Pain Management (open on stockthemes)

Last updated

Theme thesis · 3/5 sections · Tickers 5 with notes · 7 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Pain-management biotechnology and pharmaceutical companies develop or commercialize medicines for acute, chronic, postsurgical, neuropathic, musculoskeletal and

Thesis

Pain-management biotechnology and pharmaceutical companies develop or commercialize medicines for acute, chronic, postsurgical, neuropathic, musculoskeletal and migraine-related pain. The theme captures non-opioid sodium-channel inhibitors, sustained-release local anesthetics, neuropathic-pain drug candidates, opioid analgesic formulations, CGRP-targeted migraine medicines and other differentiated pharmacological approaches. Demand is driven by surgical procedures, chronic pain prevalence, migraine treatment utilization, clinical efficacy, opioid-sparing treatment adoption and reimbursement access. The basket excludes pain-management devices and treatment-service operators.

Bull case

  • Successful commercialization of selective sodium-channel inhibitors and other non-opioid analgesics expands treatment options for acute and neuropathic pain, potentially reducing reliance on conventional opioids while supporting adoption in hospitals and outpatient settings.

  • Growth in migraine diagnosis and preventive treatment utilization increases demand for CGRP-targeted antibodies, oral antagonists and combination therapies, with differentiated dosing and delivery methods expanding available patient options.

  • Advances in sustained-release anesthetics, intra-articular formulations and targeted neuropathic-pain medicines create additional treatment options for postoperative pain, osteoarthritis and chemotherapy-related neuropathy, potentially expanding reimbursed patient populations.

Bear case

  • Novel pain medicines may fail to demonstrate clinically meaningful improvements over inexpensive generic treatments, encounter adverse safety findings or face reimbursement restrictions that limit adoption despite differentiated mechanisms.

  • Patent expirations, generic competition, opioid prescribing restrictions and payer utilization controls pressure established pain portfolios, while hospital purchasing negotiations reduce pricing power for premium postoperative analgesics.

  • Clinical trial failures, inconsistent patient-reported pain endpoints, placebo responses and uncertain long-term efficacy can delay approvals or eliminate development-stage programs, particularly in chronic neuropathic pain and migraine.

Overview

Hiring Trend Watchpoints

High-performing pain management operators are prioritizing specialized commercial field teams, dedicated market access liaisons, and clinical talent navigating complex subjective endpoints. In commercial execution, monitor recruitment for hospital systems account managers, Ambulatory Surgery Center (ASC) reimbursement navigators, and Pharmacy & Therapeutics (P&T) committee specialists tasked with driving formulary inclusion under NOPAIN Act separate reimbursement pathways. In medical affairs, look for expansion of Medical Science Liaisons (MSLs) in orthopedic surgery, anesthesiology, and neurology to educate prescribers away from default opioid regimens toward selective sodium channel blockers (NaV1.8/NaV1.7) and novel CGRP/AAK1 pathways. In R&D, clinical development hires reflect expertise in managing placebo responses and subjective pain scales (e.g., SPID-48, numeric rating scales) for neuropathic indications like diabetic peripheral neuropathy. Signals confirming execution include growing institutional sales and market access headcount alongside targeted medical education teams. Conversely, commercial field freeze notices, cuts to hospital sales teams, or retrenchment to contract sales forces indicate sluggish hospital adoption or prohibitive prior authorization barriers.

Forum Watchlist

  • reddit — r/migraineHigh

    Real-world patient adherence, tolerability, insurance coverage denials, and switching dynamics between oral CGRP gepants (Nurtec, Qulipta, Zavzpret) and injectable CGRP mAbs (Ajovy, Emgality, Aimovig)

  • reddit — r/ChronicPainHigh

    Patient sentiment on accessing non-opioid analgesics, efficacy reports on new NaV1.8 treatments (Journavx/suzetrigine), and feedback on transitions from legacy opioid regimens

  • specialist_community — Sermo - Anesthesiology & Pain MedicineHigh

    Surgical and interventional pain physician commentary on institutional hospital formulary reviews, NOPAIN Act coding, and real-world efficacy of sustained-release anesthetics (Exparel) vs oral NaV1.8 blockers

  • specialist_community — Student Doctor Network - Pain Management ForumMedium

    Fellowship and attending physician discussions on interventional pain techniques, uptake of novel intra-articular treatments (Zilretta), and hospital protocol shifts toward non-opioid acute analgesia

  • reddit — r/BiotechMedium

    Industry-insider discussions regarding clinical trial pipeline readouts for NaV1.7/1.8 targets, AAK1 inhibitors, and M&A activity across pain management biotechs

Industry Publications

  • Pain Medicine News (painmedicinenews.com) — Premier clinical newspaper covering acute and chronic pain therapeutics, interventional procedures, clinical trial readouts, and FDA actions on novel analgesics.
  • Anesthesiology News (anesthesiologynews.com) — Essential coverage of perioperative care, hospital and ASC anesthesia protocols, sustained-release local anesthetics, and institutional adoption of non-opioid surgical pain regimens.
  • Fierce Pharma (fiercepharma.com) — In-depth tracking of commercial pharmaceutical launches, payer access decisions, formulary placements, and regulatory updates across the migraine and pain landscapes.
  • BioPharma Dive (biopharmadive.com) — Rigorous reporting on biotechnology clinical trial developments, neurological and analgesic drug pipelines, capital raising, and biopharma partnership transactions.
  • Endpoints News (endpts.com) — Top biotech trade publication tracking early- and late-stage pain asset data, FDA advisory committees, regulatory approvals, and corporate strategy in novel pain mechanisms.

Second Order Trends

Several pivotal second-order trends are accelerating across the pain management theme: 1. NOPAIN Act Outpatient Catalysts: The operationalization of the NOPAIN Act by CMS provides separate Medicare reimbursement in Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) for qualifying non-opioid analgesics, removing the legacy bundled-payment penalty that previously favored cheap generic opioids. 2. Pipeline Expansion from Acute to Chronic Neuropathic Pain: Having validated the NaV1.8 mechanism in postoperative acute pain (e.g., suzetrigine), companies are expanding selective sodium channel and AAK1 programs into high-prevalence chronic indications, including painful diabetic peripheral neuropathy (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN). 3. Commercial Reimbursement Friction and PSP Bridging: Branded novel pain medications face steep early friction via payer prior authorizations and restrictive step therapy, forcing manufacturers to carry higher-than-expected Patient Support Program (PSP) bridge coverage that dampens near-term gross-to-net realization until formulary status normalizes. 4. CGRP Evolution Toward Specialty Delivery and Indications: The mature migraine market is shifting toward differentiated delivery mechanisms (e.g., Zavzpret nasal spray, oral gepants) and label expansion into episodic cluster headache and menstrual migraine to insulate against future competitive pressure. 5. Multi-Targeted Peripheral Ion-Channel Modulation: In response to functional redundancy across sensory nerves, next-wave biotechs are advancing dual NaV1.7/1.8 channel silencers and charged nocion formulations to enhance peripheral analgesia without systemic CNS adverse effects.

Search Keywords Brand Product

  • JOURNAVX
  • suzetrigine
  • EXPAREL
  • ZILRETTA
  • NURTEC ODT
  • Qulipta
  • Ubrelvy
  • Zavzpret
  • Ajovy
  • Emgality
  • Aimovig
  • SYMBRAVO
  • BELBUCA
  • Xtampza ER
  • Nucynta
  • pilavapadin
  • Halneuron
  • RAP-641
  • non-opioid analgesics
  • acute pain management
  • neuropathic pain
  • migraine therapy
  • postsurgical analgesia
  • sodium channel blockers
  • CGRP receptor antagonists
  • chronic pain therapeutics

Search Keywords Policy Regulatory

  • NOPAIN Act
  • CMS OPPS ASC payment rule
  • Medicare Part B separate payment
  • FDA non-opioid analgesic guidance
  • opioid prescribing limits
  • prior authorization requirements

Search Keywords Event Phrases

  • Non-Opioid Pain Therapeutics Summit
  • American Academy of Pain Medicine Annual Meeting
  • American Society of Anesthesiologists Annual Meeting
  • American Headache Society Annual Scientific Meeting
  • PDUFA action date
  • Phase 3 topline readout

Google Trend Product Category Intent

• Journavx coupon • Exparel injection knee replacement • Nurtec ODT side effects • Qulipta prescription • suzetrigine FDA approval • Zavzpret nasal spray

Google Trend Consumer Intent

• non-opioid pain relief after surgery • best migraine prevention medication • alternatives to opioids for post surgery • diabetic nerve pain treatments • chronic migraine new drugs

Google Trend Macro Policy Terms

• NOPAIN act Medicare • opioid crisis legislation • non opioid pain coverage • CMS outpatient non-opioid reimbursement

Economic Data Watch

1. FRED — Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field PCEPI

Cadence monthly

Why it matters Growth in personal consumption expenditures on healthcare indicates the overall market demand and spending capacity for medical treatments, including pain management therapies.

Signal to watch Sustained increase in healthcare consumption expenditures is bullish, suggesting a growing market for pharmaceutical products.

Confidence: high

2. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field CPIMEDNS

Cadence monthly

Why it matters The Consumer Price Index for medical care reflects inflation and pricing trends within the healthcare sector, impacting the cost of goods and potential revenue for pharmaceutical companies.

Signal to watch Moderate and stable medical care CPI is generally neutral to bullish, while rapidly accelerating CPI could signal pricing pressures or increased input costs.

Confidence: high

3. FRED — Retail Sales

Matchedfred · access=api · map_only

Metric/field RSXFS

Cadence monthly

Why it matters Overall retail sales indicate consumer spending strength, which can indirectly affect out-of-pocket spending on prescription drugs and elective pain treatments.

Signal to watch Sustained growth in retail sales is bullish, indicating a healthy consumer economy that can support healthcare spending.

Confidence: high

4. FRED — Unemployment Rate

Matchedfred · access=api · map_only

Metric/field UNRATE

Cadence monthly

Why it matters The unemployment rate impacts the number of insured individuals and their ability to afford healthcare services and prescription medications, directly affecting patient access and demand.

Signal to watch A declining unemployment rate is bullish, suggesting broader insurance coverage and greater affordability for patients.

Confidence: high

5. FRED — Manufacturers' Shipments

Matchedfred · access=api · map_only

Cadence monthly

Why it matters Shipments of drugs and pharmaceuticals serve as a proxy for production and demand within the broader pharmaceutical manufacturing sector, reflecting overall industry activity.

Signal to watch Increasing shipments are bullish, indicating robust production and demand for pharmaceutical products.

Confidence: low

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Study Status, Last Update Posted

Cadence event_driven

Why it matters Monitoring the status and updates of clinical trials for pain management drugs provides early indicators of pipeline progress, potential future product launches, and competitive landscape shifts.

Signal to watch Advancement of trials to later phases, positive interim results, or completion of enrollment are bullish signals for pipeline development.

Confidence: high

2. FDA — Drug Approvals and PDUFA Dates

Not in registry

Metric/field New Drug Approvals, PDUFA Dates

Cadence daily

Why it matters FDA approvals are critical milestones for commercialization, directly impacting revenue potential and market entry for new pain management therapies or expanded indications.

Signal to watch Timely FDA approvals or positive PDUFA outcomes are bullish, indicating successful regulatory navigation and market access.

Confidence: high

3. USPTO PatentsView — Patent Grants and Applications

Not in registry

Metric/field Patent Grants, Patent Applications

Cadence weekly

Why it matters Patent activity indicates innovation and intellectual property protection, which are vital for pharmaceutical companies to maintain market exclusivity and competitive advantage for their pain management drugs.

Signal to watch An increase in patent grants or applications related to pain management is bullish, suggesting ongoing R&D and future market protection.

Confidence: high

4. Google Trends — Search Interest

Not in registry

Metric/field Search interest for key drug brands

Cadence weekly

Why it matters Changes in search interest for specific pain management drugs or related conditions can indicate growing patient awareness, physician prescribing trends, and overall market demand.

Signal to watch Sustained or increasing search interest for theme-relevant drugs is bullish, suggesting rising adoption or interest.

Confidence: medium

5. SEC EDGAR — 8-K Filings

Not in registry

Metric/field Full-text search for clinical trial results, regulatory milestones, M&A

Cadence event_driven

Why it matters 8-K filings provide timely disclosure of material events, including clinical trial outcomes, regulatory decisions, and strategic partnerships, which are critical for assessing company performance and future prospects.

Signal to watch Positive announcements regarding clinical data, regulatory approvals, or strategic collaborations are bullish signals.

Confidence: high

Paid Alt Data Watch

1. IQVIA — Healthcare Claims / Rx

Matchediqvia_medical_claims · access=file · map_only

Metric/field Total Prescriptions (TRx) and New-to-Brand Prescriptions (NBRx)

Cadence weekly

Why it matters Real-time prescription data offers direct insight into market adoption, patient uptake, and competitive dynamics for pain management drugs, indicating commercial success.

Signal to watch Consistent growth in TRx and NBRx for key products is bullish, demonstrating strong market penetration and demand.

Confidence: high

2. Symphony Health — Healthcare Claims / Rx

Matched (medium)symphony_health_medical_claims · access=file · map_only

Metric/field Market Share by Drug and Therapeutic Area

Cadence monthly

Why it matters Tracking market share provides a clear picture of how individual drugs and companies are performing against competitors within specific pain management therapeutic areas.

Signal to watch Increasing market share for theme-relevant products is bullish, indicating competitive strength and commercial execution.

Confidence: high

3. Komodo Health — Healthcare Claims / Rx

Matched (medium)komodo_health_medical_claims · access=file · map_only

Metric/field Patient Journey Analytics for Pain Conditions

Cadence monthly

Why it matters Detailed patient journey data can reveal insights into treatment patterns, unmet needs, and the effectiveness of different pain management therapies in real-world settings.

Signal to watch Increased patient starts on novel therapies and improved adherence rates are bullish, suggesting positive patient outcomes and market acceptance.

Confidence: high

4. Earnest Analytics — Consumer Transaction Data

Matched (medium)earnest_analytics_credit_debit_card_consumer_spend · access=file · map_only

Metric/field Out-of-pocket spending on prescription pain medications

Cadence weekly

Why it matters Direct consumer spending data on prescription pain medications can highlight trends in patient affordability, willingness to pay for premium drugs, and the impact of insurance coverage.

Signal to watch Growth in out-of-pocket spending on novel or premium pain medications is bullish, indicating strong consumer demand and perceived value.

Confidence: medium

5. GlobalData Healthcare — Market / Industry Research

Matchedglobaldata_healthcare_healthcare_forecasts_market_sizing · access=file · map_only

Metric/field Pain Management Market Forecasts and Pipeline Analysis

Cadence quarterly

Why it matters Industry research and forecasts provide expert analysis on market size, growth drivers, competitive landscape, and future trends in the pain management sector, informing investment decisions.

Signal to watch Upward revisions in market forecasts or positive assessments of pipeline assets are bullish, indicating strong growth prospects.

Confidence: high

Prediction Market Watch

1. When will CMS announce the addition of GLP-1 drugs for obesity to Part D? (Before Jan 20, 2029)

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxpartdglp1

Why it matters A CMS announcement adding GLP-1 drugs for obesity to Part D would significantly expand market access and reimbursement for these medications. This would directly benefit theme constituents like Eli Lilly (LLY) and Amgen (AMGN), whose GLP-1 programs (Mounjaro, Zepbound, Foundayo for LLY; MariTide for AMGN) are major revenue drivers and are highlighted as key growth catalysts in their respective bull cases. Increased coverage would likely lead to higher prescription volumes and revenue growth for these companies.

Series key kalshi_cms_partd_glp1_approval

2. Will the FDA approve a cure for Type 1 diabetes before 2033?

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxfdatype1diabetes

Why it matters FDA approval of a cure for Type 1 diabetes would be a transformative event for Vertex Pharmaceuticals (VRTX), a theme constituent. Vertex is actively developing VX-017, a universal donor cell product for Type 1 Diabetes, which is anticipated to significantly expand its addressable market. A successful approval would validate Vertex's T1D strategy and pipeline, leading to substantial long-term revenue growth and a positive impact on its stock price within the theme.

Series key kalshi_fda_t1d_cure_approval

Theme Plain English
Biotech '25: Pain Management captures biopharmaceutical companies developing and commercializing therapies for acute, postsurgical, neuropathic, musculoskeletal, and migraine-related pain. The theme spans next-generation non-opioid analgesics—notably selective NaV1.8 and NaV1.7 sodium channel inhibitors—alongside sustained-release local anesthetics, CGRP-targeted migraine preventives and abortives, and abuse-deterrent formulations. As policy initiatives like the NOPAIN Act incentivize non-opioid adoption, the space is shifting from legacy opioids toward targeted, non-addictive mechanisms across outpatient surgical, hospital, and chronic disease settings.
Upcoming Catalysts13 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
LLY_10dadbebby year end2026-10-012026-12-31European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion.This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_48d9403dlater this year2026-10-012026-12-31Readout of Foundayo Phase 3 trial in obstructive sleep apnea.Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_696cb569later this year2026-10-012026-12-31U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes.This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_cf82d1b5a few markets late in 20262026-10-012026-12-31Launch of Orforglipron in a few international markets (e.g., UAE).This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration.Ticker2026-02-04earnings_transcriptLLY (ticker)
ABBV_c5da1469later this year2026-10-012026-12-31US regulatory approval decision for RINVOQ for the treatment of vitiligo.This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications.Ticker2026-07-31earnings_transcriptABBV (ticker)
AMGN_fe4d51bfWe will update you on those discussions as necessary.2026-04-242026-12-31Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication.The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory.Ticker2026-02-03earnings_transcriptAMGN (ticker)
PFE_fe771000fourth quarter2026-10-012026-12-31First readout of the MEVPRO-1 Phase III study for mevrometostat in post-abiraterone metastatic hormone-resistant prostate cancer.This pivotal study readout could establish mevrometostat as a breakthrough therapy, delaying resistance to XTANDI and representing a 100% global commercial opportunity for Pfizer.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_0a01f9d3later this year at a conference2026-09-012026-12-31Presentation of the full data set from the TRANQUILLO 1 and 2 studies for Litfulo in nonsegmental vitiligo.The full data presentation will provide comprehensive insights into Litfulo's clinically meaningful and statistical efficacy, reinforcing its potential in the vitiligo market.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_a3b83d3fthis year2026-09-012026-12-31Start of a pivotal trial investigating NURTEC's use as a treatment for chronic migraine.This pivotal trial initiation aims to expand NURTEC's label, further strengthening Pfizer's leadership in providing treatment options for migraine patients.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_a1fcc382later this year2026-09-012026-12-31Release of the clinical trial design for the adjuvant study of atirmociclib in ER-positive breast cancer.This milestone is crucial for advancing atirmociclib, which is believed to be highly differentiated in the early adjuvant setting due to its tolerability profile, representing a significant opportunity.Ticker2026-08-04earnings_transcriptPFE (ticker)
VRTX_c280265cNovember 30 PDUFA date2026-11-302026-11-30FDA PDUFA date for Pove in IgAN.This is a pivotal regulatory decision for a potential best-in-class therapy, establishing a new multibillion-dollar renal franchise for Vertex.Ticker2026-08-03earnings_transcriptVRTX (ticker)
LLY_a24ab55bDecember 7th2026-12-072026-12-07Lilly Innovation Day.This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_a075099bQ1 20272027-01-012027-03-31U.S. regulatory submission (BLA pathway) for retatrutide.This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss.Ticker2026-10-29earnings_transcriptLLY (ticker)

Loading correlation…

Constituents

  • LLYT13.5%
    — Eli Lilly and Company
  • — AbbVie Inc.
  • — Amgen Inc.
  • PFET3
    — Pfizer Inc.
  • — Vertex Pharmaceuticals Incorporated
  • AXSMT3
    · no notes yet
  • COLLT3
    · no notes yet
  • DWTXT3
    · no notes yet
  • LXRXT3
    · no notes yet
  • PCRXT3
    · no notes yet
  • RAPPT3
    · no notes yet
  • TEVAT3
    · no notes yet